These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7439983)

  • 1. Improved protection against cholera in adult rabbits with a combined flagellar-toxoid vaccine.
    Resnick IG; Ford CW; Shackleford GM; Berry LJ
    Infect Immun; 1980 Nov; 30(2):375-80. PubMed ID: 7439983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flagella-induced immunity against experimental cholera in adult rabbits.
    Yancey RJ; Willis DL; Berry LJ
    Infect Immun; 1979 Jul; 25(1):220-8. PubMed ID: 478635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits.
    Eko FO; Schukovskaya T; Lotzmanova EY; Firstova VV; Emalyanova NV; Klueva SN; Kravtzov AL; Livanova LF; Kutyrev VV; Igietseme JU; Lubitz W
    Vaccine; 2003 Sep; 21(25-26):3663-74. PubMed ID: 12922096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.
    Murugaiah C; Nik Mohd Noor NZ; Mustafa S; Manickam R; Pattabhiraman L
    PLoS One; 2014; 9(2):e81817. PubMed ID: 24505241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic immunity of experimental animals immunized with cholera vaccines].
    Genova IuG; Bogatinov VT; Manakhilov RB; Kostova EF
    Zh Mikrobiol Epidemiol Immunobiol; 1987 Nov; (11):41-4. PubMed ID: 3434048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine.
    Peterson JW
    Infect Immun; 1979 Nov; 26(2):528-33. PubMed ID: 546785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.
    Xian TH; Sinniah K; Yean CY; Krishnamoorthy V; Bahari MB; Ravichandran M; Prabhakaran G
    BMC Immunol; 2020 May; 21(1):29. PubMed ID: 32450807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J; Mazumder R; Srivastava R; Srivastava BS
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
    Stewart-Tull DE; Lucas C; Bleakley CR
    Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
    Taylor DN; Tacket CO; Losonsky G; Castro O; Gutierrez J; Meza R; Nataro JP; Kaper JB; Wasserman SS; Edelman R; Levine MM; Cryz SJ
    Infect Immun; 1997 Sep; 65(9):3852-6. PubMed ID: 9284163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulins in bile and serum of the rabbit associated with protection after Vibrio cholerae infection and vaccination.
    Rijpkema SG; Jansen WH; Gielen H; Guinée PA
    Microb Pathog; 1987 Nov; 3(5):365-75. PubMed ID: 2462153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of surface components of Vibrio cholerae as protective immunogens.
    Eubanks ER; Guentzel MN; Berry LJ
    Infect Immun; 1977 Feb; 15(2):533-8. PubMed ID: 844905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate.
    Levine MM; Black RE; Clements ML; Young CR; Lanata C; Sears S; Honda T; Finkelstein R
    Dev Biol Stand; 1983; 53():59-65. PubMed ID: 6873477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.
    Liang W; Wang S; Yu F; Zhang L; Qi G; Liu Y; Gao S; Kan B
    Infect Immun; 2003 Oct; 71(10):5498-504. PubMed ID: 14500467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses.
    Yang JS; Kim HJ; Yun CH; Kang SS; Im J; Kim HS; Han SH
    J Microbiol Methods; 2007 Nov; 71(2):141-6. PubMed ID: 17888533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of mesoporous silica and carbon nanoparticles in antigen stability and intensity of immune response against recombinant subunit B of cholera toxin in a rabbit animal model.
    Karimi Bavandpour A; Bakhshi B; Najar-Peerayeh S
    Int J Pharm; 2020 Jan; 573():118868. PubMed ID: 31765785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.